Pharmascience Inc.

33 articles about Pharmascience Inc.

• Pharmascience Expands its Contract Development and Manufacturing Organization (CDMO) Services With a New Commercial Business Unit

  2/26/2024

  Last Fall, Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site.

• Discover this new generic drug in the PERINDOPRIL range

  2/21/2024

  Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE, a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate.

• PHARMASCIENCE INC. ANNOUNCES APPOINTMENT OF MARTIN ARES AS NEW CHIEF EXECUTIVE OFFICER

  11/16/2022

  Pharmascience Inc. is pleased to announce today the appointment of Martin Arès as Chief Executive Officer, effective January 3, 2023.

• Pharmascience International Launches its first Generic of Pazopanib 200 mg & 400 mg in Bulgaria

  7/5/2022

  Pharmascience is proud to announce additional great news with the launch of Pazopanib 200 MG & 400 MG generic in Bulgaria.

• Pharmascience Canada is thrilled to launch (PR)pms-TERIFLUNOMIDE

  5/27/2022

  Pharmascience Canada, a division of Pharmascience Inc. is proud to launch PRpms-TERIFLUNOMIDE, a generic drug with demonstrated bioequivalence to the brand name AUBAGIO®.

• Appointment of Roger-Ketcha Ngassam as Vice President, Operations

  4/13/2022

  Pharmascience is pleased to welcome a new member to its executive team, Roger-Ketcha Ngassam, who will join the team on April 4 as Vice President of Operations.

• Generic Drug Repurposing in Canada - A Canadian Manufacturer's Perspective

  4/8/2022

  Pharmascience Inc. presents its recommendations for encouraging drug repositioning.

• Morris Goodman, Co-founder and Chairman of the Board of Pharmascience Inc. is appointed to the Order of Canada

  1/3/2022

  Pharmascience Inc. is extremely proud of the appointment of Morris Goodman, Co-founder and Chairman of the Board, as a Member of the Order of Canada by Her Excellency the Right Honourable Mary Simon, Governor General of Canada.

• Information Update - Update: Pharmascience Inc. recalls certain lots of over-the-counter ranitidine

  12/3/2021

  Pharmascience Inc. is recalling 18 lots of over-the-counter ranitidine drugs after tests found NDMA, a nitrosamine impurity, close to and above the acceptable level.

• Pharmascience inc. lowers the price of pms-Sodium Cromoglycate 1% Nebulizer Solution until inventories are depleted

  12/1/2021

  As treatment standards and options evolve towards the use of new medicines to treat medical conditions, the use of many older, affordable generic medicines such as pms-Sodium Cromoglycate 1% nebulizer solution has decreased significantly.

• Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies

  8/24/2021

  Pharmascience Inc. is recalling one lot of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules.

• Pharmascience Inc. Selects Exasol to Provide End-Users with Lightning-Fast Access to Data

  2/16/2021

  Exasol, the high-performance analytics database, announced that Pharmascience Inc., a leading Canadian manufacturer of prescription, over-the-counter, and behind-the-counter generic pharmaceuticals, has selected Exasol to give end-users faster, more efficient access to data.

• Pharmascience Inc. launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the maintenance treatment of asthma and COPD

  3/18/2020

  Pharmascience Inc. is proud to bring to market a new product for the maintenance treatment of asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic alternative to ADVAIR DISKUS™ is now available in Canada in the same inhaler device as *ADVAIR DISKUS™.

• Pharmascience Inc. contributes to the Montreal Heart Institute's COLchicine Cardiovascular Outcome Trial (COLCOT), a landmark study to benefit cardiovascular patients and the healthcare system

  11/16/2019

  The Montreal Heart Institute announced earlier the results of its COLchicine Cardiovascular Outcomes Trial

• Pharmascience's generic Paliperidone Palmitate Prolonged-Release Injectable Suspension received for review by the FDA

  11/12/2019

  Pharmascience Inc. is proud to announce that the US Food and Drug Administration (FDA) communicated on October 31, 2019, that the abbreviated new drug application (ANDA) for Pharmascience's generic version of Paliperidone Palmitate Extended-Release Injectable Suspension prefilled syringes, is accepted for review

• Pharmascience Inc. launches pms-FINGOLIMOD for the treatment of relapsing-remitting multiple sclerosis (MS) in adults

  10/31/2019

  Pharmascience is proud to launch pms-FINGOLIMOD. A generic drug with demonstrated bioequivalence to the brand product GILENYA® for the treatment of relapsing multiple sclerosis (MS) in adults

• Information Update - Additional ranitidine products recalled as a precautionary measure; request to stop distribution remains in place while Health Canada continues to assess NDMA

  10/26/2019

  Dominion Pharmacal, Laboratoire Riva Inc., Pharmascience Inc. and Vita Health Inc. are recalling all lots of their prescription and over-the-counter ranitidine products from the Canadian market as a precautionary measure.

• Pharmascience Inc. issues voluntary recall of Ranitidine Tablets 75mg, 150mg and 300mg (all pack sizes and formats)

  10/24/2019

  Pharmascience Inc. is voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg, 150mg and 300 mg to the retail level.

• Pharmascience Inc. launches Royalmount Laboratories, a new analytical service division in Montreal

  5/10/2019

  Pharmascience Inc. is proud to announce the launch of its new division in Montreal, Royalmount Laboratories.

• Pivot Pharma Signs Letter of Intent with Pharmascience Inc.

  4/3/2019

  Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that it has signed a Letter of Intent, dated February 26th, 2019, with Pharmascience Inc.